Mercury ban will hit exporters to Europe
This article was originally published in Clinica
Executive Summary
The European Commission's proposal to ban mercury in medical instruments sold to the general public would only impact a small number of small to medium-sized enterprises (SMEs) in the EU. But companies exporting to the EU from China, India and Japan are likely to be badly hit. That is the Commission's view, as expressed in its Impact Assessment of the proposal that it has just published (see Clinica No 1194, p 4).
You may also be interested in...
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.